



Date: 6 December 2017

Sydney, Australia

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

NOX OPEN BRIEFING CORPORATE PRESENTATION

Sydney, 6 December 2017: Noxopharm (ASX: NOX) and its US subsidiary, Nyrada Inc, are pleased to release their respective corporate presentations to be delivered today to an Open Briefing for shareholders and investors.

The Briefing will review:

- the Noxopharm clinical trial program for NOX66
- the anticipated key milestones for NOX66
- the Nyrada, Inc strategy.

Details of the Open Briefing are as follows:

Time: 12.30 pm – 1.30 pm
Venue: Level 41, 259 George St Sydney

.....

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy. NOX66 is the first pipeline product, with later generation drug candidates under development.

About Nyrada Inc.

Nyrada Inc is a US biotechnology company, established as a subsidiary of Noxopharm to focus on non-oncology drug development. Nyrada has 3 drug assets: NYX-104 (excitotoxicity inhibitor), NYX-205 (anti-inflammatory), NYX-330 (PCSK9 inhibitor).

Investor & Corporate Enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 9299 9690
E: dfranks@fa.com.au

www.noxopharm.com

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

Open Briefing 6 December 2017





NOXOPHARM

The logo for Noxopharm features a stylized blue and grey geometric symbol above the company name 'NOXOPHARM' in a bold, black, sans-serif font. The text is flanked by horizontal lines.

ONCOLOGY

Noxopharm



NOX66

Idronoxil (lipophilic form)

ABOUT IDRONOXIL


Multiple anti-cancer actions

1. Inhibits DNA repair


(inhibits PARP-1, topoisomerases 1 and 2)

2. Promotes anti-tumour immunity

(Increases NK (natural killer) cell activity)




Oral Idronoxil



**Excreted quickly
(45 min)**

**Does NOT
cross BBB**

NOX66



**LIPROSE
Technology**

**Excreted slowly
(10 hours)**

Crosses BBB

DARRT


Direct and Abscopal Response to Radio-Therapy

Limitation of radiotherapy

Metastatic cancer too extensive for radiation




Noxopharm




DIRECT Response to Radio-Therapy

Noxopharm




Radiotherapy applied to large tumours for pain relief




Shrinkage of irradiated tumours

DIRECT Response to Radio-Therapy


Noxopharm



Radiotherapy applied to large tumours for pain relief



Shrinkage of irradiated tumours



NOX66


Seeking **complete remission** of irradiated tumours

ABSCOPAL Response to Radio-Therapy


Noxopharm

Exposed tumours respond


+ Non-exposed tumours also respond



Low-dose radiotherapy



Seeking **complete remission** of irradiated tumours



Abscopal response


Features of an abscopal response

- Rare*** – very rare phenomenon
- Complete*** – primary AND secondary tumours respond
- Durable*** – potentially permanent
- Unrestricted*** – range of cancers reportedly involved
- Short treatment*** – single course of treatment (7-14 days)
- Low toxicity*** – low-grade radiation sickness

Direct Effect

Abscopal Effect

- Patients with multiple (>3) tumours
- Irradiate 1-2 tumours (5 days)
- NOX66 14 days
- Scan + 2 months and 4 months



External Beam RT

Direct Effect

Abscopal Effect


- Prostate cancer (metastatic castrate-resistant)
- Solid common cancers (eg. lung, breast, melanoma)
- Rare cancers (eg. sarcomas)



External Beam RT

Direct Effect

Abscopal Effect



Brachytherapy

- 177 Lutetium-PSMA-617
- 4 x monthly intravenous injections of LuPSMA/10 days NOX66
- Prostate cancer (metastatic castrate-resistant)

DARRT

Noxopharm

Where NOX66 + Radiotherapy needs a boost

NOX66-001 Phase 1b Study Georgia

+ Low-dose carboplatin (AUC4 – monthly)

400 mg NOX66

5 patients: 1 progressive; 4 non-progressive

800 mg NOX66

7 patients: 1 progressive; 5 non-progressive;
1 partial response

What will a 'good response' look like ?

- Lung Cancer trial (**582 patients** evaluated)
- Opdivo vs standard chemotherapy
 - Survival of 50% of patients - **12.2 months v 9.4 months**
 - Time to disease progression – **2.3 months v 4.2 months**
 - Overall Response Rate – **19% v 12%**
 - Four Complete Responses v One
 - Adverse Reactions (**>20% of patients**) - fatigue, musculoskeletal pain, cough, breathing difficulty, decreased appetite

- US\$150,000 treatment cost
- Sales for first 6 months 2016 = US\$1.6 billion

Moving towards first registration

Target Indication: NOX66 in combination with Radiotherapy for the treatment of patients with metastatic cancer

Studies:

NOX66-002A: Determine Dose of NOX66 (Prostate Cancer)

NOX66-006: Open Label, all tumours. Safety and efficacy

NOX66-007: Randomised, 2-3 tumours. Efficacy in comparison to standard care

LuPIN Study: ¹⁷⁷Lu-PSMA and NOX66 (Prostate Cancer): Supporting registration

Expansion of ¹⁷⁷Lu-PSMA research

Other Radiotherapy Research (supportive data, for expanded indication in future) – e.g. brain, paediatrics, stereotactic, brachytherapy etc.

Submit for Registration

2017

2018



2019

2020/21

Notes:

- Different Global Regulators may modify indication for specific tumour types
- Indication may also list when treatment can be used
- Indication will discuss how to use Radiotherapy with NOX66
- Rare cancers may not be included in indication, however evidence is important
- Reimbursement is as important as Registration

Beyond the trials to reach registration

- **Manufacturing and formulation:** Optimise NOX66 formulation; GMP Manufacturing
- **Pre-clinical / non-clinical:** *in vitro* and animal studies to meet regulatory and other requirements for registration and marketing
- **Medical Affairs:** Liaison with oncologists, advisory boards, congress attendance and presentation 
- **Marketing:** Develop Noxopharm presence, brand-naming, commercialization (including pricing) strategy 

Communicating Trials Progress 2018

- Progress – based on Data Safety Monitoring Committee Review
 - Independent body – researchers and statisticians
 - Regular meetings during trials – expect ~6 across trials in 2018
 - Review overall progress → decisions on continuation
 - Findings of DSMBs will be communicated
- Trial Data at conferences
 - Contingent on significant milestones in trials (end of study, all patients through a pre-defined time point) – expect ~4 in 2018
 - Requires considerable planning (e.g. ASCO – meeting June, submit presentation in February)
 - Requirement that data are embargoed until presented
 - Where significant outcomes, top line result may be released as per ASX requirements prior to conference




Nyrada
inc


2 technologies



3 drugs



3 indications



- ❖ Stroke
- ❖ Concussion
- ❖ Severe epilepsy




Peripheral neuropathy




Hypercholesterolaemia

NYX-104


Inhibitor of *excitotoxicity*




NYX-104



Excitotoxicity



Size of original area of damage from stroke or concussion




Days to weeks later, excitotoxicity has increased area of damage up to **10-times**

NYX-104



1. University of NSW Translational Neuroscience Facility:
Breakthrough identification of key protein
promoting excitotoxicity (**TrpC3 isotope**)





2. *In vitro* screen of NOX compounds:
NYX-104 inhibits TrpC3

3. Mouse model of human stroke:
NYX-104 is potent inhibitor of excitotoxicity.
70% reduction in area of brain death post-stroke.

NYX-205

*Anti-inflammatory
Designed to cross the blood-nerve barrier*



NYX-205


Peripheral neuropathy



Incidence in US estimated at 20 million:

- Diabetes
- Alcohol abuse
- Chemotherapy

Blood-nerve barrier is major obstacle to effective treatment. NYX-205 designed to cross this barrier.



Typical Peripheral Neuropathy Symptoms

- ✓ Loss of Feeling
- ✓ Freezing
- ✓ Tingling
- ✓ Numbness
- ✓ Hyper Sensitivity
- ✓ Sharp Jabbing Pain
- ✓ Burning Sensation

NYX-205


Peripheral neuropathy



Targeting peripheral neuropathy in cancer patients receiving chemotherapy


60% incidence at 3 months
30% incidence at 6 months

Currently no effective treatment



NYX-330

Hypercholesterolemia



NYX-330

Hypercholesterolemia




- **PCSK9** identified as superior drug target compared to statin drugs for lowering blood LDL levels.
- **PCSK9** is plasma protein that binds to the LDL-LDL receptor complex, preventing recycling of the LDL receptor and thereby increasing LDL levels.



PCSK9 declared an unsuitable target for small molecule drug. Amgen develops monoclonal antibody. **Repatha** comes to market in 2015.

NYX-330

Hypercholesterolemia



Suitable binding site identified on **PCSK9** for attachment of small molecule.

NYX-330 blocks binding of PCSK9 to LDL- LDL receptor complex.



- US-registered
- Focus on small molecules, non-oncology
- 67% owned by NOX; 33% Altnia Holdings
- Currently public unlisted; proposed US listing in 12-18 months



OFFER:

- Raise = AUD\$6,000,000
- Seed capital = 1,500,000 New Shares (A\$4 each; 2 Options per 3 Shares)
- Capital structure post-exercise of Options
 - NOX 50%
 - Altnia 25%
 - Seed investors 25%

Application for Shares by sophisticated investors, non-US residents only.
Information Memorandum available: info@nyrada.com

Disclaimer

- This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.
- This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.
- This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.
- Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.
- Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.



www.nyrada.com



NOXOPHARM

